Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3

Parabilis Medicines just set a record — six hundred seventy million dollars, the largest venture-backed biotech IPO ever — and it's the second time that record has fallen in two months.

Meanwhile, Sanofi kills a Phase 3 complement trial, TG Therapeutics pops double digits on Briumvi myasthenia gravis data, and AstraZeneca's oral GLP-1 puts up numbers that will keep this obesity race interesting. Busy Wednesday.

Welcome to The Pharma Closeout for Wednesday, June tenth, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Parabilis Medicines priced at twenty dollars a share today, raising six hundred seventy million dollars for its cancer pipeline — the lead program, zolucatetide, targets desmoid tumors. To put the trajectory in perspective: Moderna's IPO held the venture-backed biotech record for nearly a decade. Kailera posted a significant fundraise last month. Parabilis just blew past both.

Two records in two months says more about the capital environment than it does about any single company. Investors are sprinting into oncology IPOs like the window has an expiration date.

And it might. Here's the macro overlay — May CPI came in at four point two percent today, the hottest reading since April twenty twenty-three, driven by the Hormuz energy shock feeding through. Fed-hike odds are surging. So you've got biotech IPOs breaking records while the cost of capital is actively worsening.

Those two things can't coexist indefinitely. Either rates stabilize and the IPO momentum continues, or inflation stays hot and the window shuts — possibly fast. For companies still in the queue, today's Parabilis print isn't just a headline. It's a starting gun.

The broader twenty twenty-six numbers back that up. Twelve drug startups have now raised more than four point one billion dollars combined through IPOs, with a median raise of about three hundred million each. That median is a significant spike from prior years. Parabilis priced above range, so institutional demand was clearly there. But whether we're looking at durable conviction or a rush to lock in pricing before conditions deteriorate — that's what separates the bulls from the bears right now.

And from a portfolio standpoint, the companies that just IPO'd into this window are sitting on full treasuries. The ones that hesitate could end up raising at a steep discount six months from now. The asymmetry favors urgency.

That urgency is showing up in private markets too. Shifting to the deal and pipeline side — Novartis and Orionis Biosciences struck their second molecular glue partnership. Forty million upfront, up to one point four billion in milestones across multiple disease areas.

Repeat partnerships tell you something that first deals don't. Novartis saw enough from the first collaboration to come back and expand scope. None of the other molecular glue players — Monte Rosa, C4 — have landed that kind of Big Pharma validation twice from the same partner.

On the equity side, TG Therapeutics jumped roughly ten percent today on Phase 1 subcutaneous Briumvi data in myasthenia gravis. Eighty-two percent of patients hit MCID on MG-ADL, with a mean improvement over four points. They're planning a Phase 2 with approximately a hundred twenty patients.

The convenience story writes itself — subcu anti-CD20 competing against established complement and FcRn mechanisms in MG. But the stock is already trading over twenty percent above its twenty-day moving average. That kind of extension invites volatility. The Phase 2 needs to deliver clean dose-response data or this trade unwinds.

And from ADA — AstraZeneca's oral GLP-1 elecoglipron showed eleven point eight percent weight loss at thirty-six weeks in VISTA Phase 2, versus zero point three on placebo. AZ is planning what they're calling an extensive late-stage program off these results. As we noted yesterday, ADA twenty twenty-six is reshaping the oral GLP-1 competitive landscape in real time.

Eleven point eight percent on an oral at thirty-six weeks is competitive within the oral class — but let's not lose sight of the injectable ceiling. Retatrutide TRIUMPH-1 data from earlier this week demonstrated robust weight loss outcomes. So the oral convenience premium needs to be massive to sustain a multi-billion dollar franchise when the efficacy gap is that stark. AZ is betting patients will choose good-enough in a pill over best-in-class in a needle. That bet works in primary care. It's less obvious in specialty.

Rapid-fire on financings — Beren Therapeutics raised three hundred million ahead of a PDUFA date for adrabetadex in Niemann-Pick disease Type C, target date November seventeenth. SonoThera pulled in a hundred twenty-five million Series B for ultrasound-aided gene therapy. Ethyreal launched with a hundred one million targeting Graves' disease and thyroid eye disease. City Therapeutics, co-founded by former Alnylam CEO John Maraganore, secured substantial funding for next-gen RNAi — they've already got a clotting disorder drug in early human testing. And Shattuck Labs raised seventy-five million after posting Phase 1 data for SL-325, their DR3 blocking antibody — a notably low antidrug antibody rate, which could be a differentiator in the TL1A inhibitor class.

Add it up and substantial capital flowed into biotech in a single day, across oncology, rare disease, gene therapy, autoimmune, and RNAi. That's not one hot sector — that's broad-based risk appetite. Explain to me how that squares with four point two percent CPI.

It doesn't. And that's exactly what makes this moment worth tracking.

On the regulatory front — Sanofi disclosed today that it's terminating the MOBILIZE Phase 3 study of riliprubart in CIDP. Riliprubart is a C1s complement inhibitor, and the trial enrolled patients refractory to standard-of-care. An independent data monitoring committee determined at interim analysis that the study was unlikely to demonstrate sufficient efficacy. Importantly, no safety signals.

So this is a clean efficacy miss, not a safety-driven halt.

Right. And the population matters here — refractory CIDP patients who've already failed standard therapy represent the hardest-to-treat end of the spectrum. Placebo-adjusted deltas in that population have been notoriously difficult to capture across mechanisms. Sanofi says they'll now evaluate whether VITALIZE, their other Phase 3 studying riliprubart in IVIg-treated CIDP patients, continues. That's a very different population — IVIg-responsive patients tend to show more measurable treatment effects. So MOBILIZE failing doesn't automatically doom the platform, but it narrows the commercial opportunity considerably and puts a spotlight on whether complement inhibition is the right mechanism for refractory nerve disease at all.

Also worth noting on the regulatory and policy front — Pfizer CEO Albert Bourla sent a letter to German Chancellor Friedrich Merz, per Reuters, reconsidering future investments in Germany over the new healthcare reform plan. That follows Lilly recently halving its planned German manufacturing investment. And separately, Teva is reducing its workforce at its for-sale API unit.

The Bourla letter is the second major pharma company pushing back on German reform inside of a month. When CEOs start putting concerns in writing to heads of state, that's not posturing — that's capital allocation signaling. Europe's pharma investment case is getting harder to make.

Looking ahead — ADA twenty twenty-six continues through the week. More late-breaking data expected, and the oral GLP-1 competitive picture remains front and center as Lilly, AZ, and Pfizer all jockey for positioning.

The House COINS Act now has a bipartisan proposal to add biotechnology to its scope — that would place greater scrutiny on licensing deals with China-based drugmakers. Still early-stage legislation, but the trajectory on US-China biotech decoupling keeps accelerating, and any company with active China licensing partnerships should be pressure-testing those structures now, not later.

Also on the forward calendar — Treeline Biosciences, led by former Loxo Oncology CEO Josh Bilenker, plans to go public via reverse merger with Standard BioTools. Three cancer drugs in early-stage testing and a pedigree that commands attention. When the person who built Loxo steps back into public markets, the sector pays attention — and so should you.

That is your Pharma Closeout for Wednesday. Parabilis smashing the biotech IPO record at six seventy, TG Therapeutics surging on Briumvi MG data, AstraZeneca planting its flag in the oral obesity race, and Sanofi walking away from riliprubart in CIDP — all on a day when inflation hit four point two percent and biotech somehow raised over a billion dollars anyway. If this briefing saves you time, follow us on Spotify and drop a rating — we'll be back tomorrow with fresh analysis on whatever lands next.

Have a great Wednesday evening, everyone. See you tomorrow.